Morgan Stanley Nanobiotix S.A. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Nanobiotix S.A. stock. As of the latest transaction made, Morgan Stanley holds 2 shares of NBTX stock, worth $6. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 2 -0.0%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 16, 2024	SELL	$6.12 - $8.13 $1,836 - $2,439	-300 Reduced 99.34%	2 $0
Q1 2024 May 15, 2024	SELL	$6.12 - $8.13 $1,836 - $2,439	-300 Reduced 99.34%	2 $0
Q4 2023 Aug 16, 2024	BUY	$5.34 - $9.19 $1,602 - $2,757	300 Added 15000.0%	302 $2,000
Q4 2023 Feb 13, 2024	SELL	$5.34 - $9.19 $7,465 - $12,847	-1,398 Reduced 82.24%	302 $2,000
Q3 2023 Nov 15, 2023	BUY	$5.03 - $10.76 $8,551 - $18,292	1,700 New	1,700 $14,000
Q4 2021 Feb 14, 2022	SELL	$7.13 - $13.04 $2,139 - $3,911	-300 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.36 - $15.0 $3,408 - $4,500	300 New	300 $3,000

Others Institutions Holding NBTX

# of Institutions

Shares Held

6.43M

Call Options Held

Put Options Held

View Full List

About Nanobiotix S.A.

Ticker NBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,875,900
Market Cap $108M
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...

More about NBTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account